For the first time in years, regulators rebuilt the flu vaccine from scratch, swapping the H1N1, H3N2, and B strains after a fast-mutating H3N2 variant cut protection in some patients to as little as 14%.

The idea that allergy pills 'stop working' after months of daily use isn't well supported by the evidence — but the FDA has flagged a real, different reaction to watch for when you quit.

Compounding pharmacies aren't FDA-approved, because that approval doesn't exist for them. Here's the regulatory split behind the copycat-Ozempic crackdown, and why claiming otherwise just got 25 telehealth firms in trouble.

A federal tracking system logs every pseudoephedrine sale in real time. Here's why Sudafed sits behind the counter, what the purchase limits actually are, and when they start to matter.

The FDA's April 2026 proposal would end large-scale compounding of semaglutide and tirzepatide. Individual-patient compounding isn't affected, but the supply picture is about to shrink.

Drug ads that name a condition and a brand are banned nearly everywhere in the world. Here's how the US and New Zealand ended up as the two exceptions.

A bottle of melatonin in an American drugstore can pack five to ten milligrams; the same supplement in France is capped under two. The regulatory gap has real consequences for how families use -- and mis-store -- a hormone most people assume is harmless.

The FDA cited Happiest Baby for selling SNOO products without clearance and flagged mold and unsanitary refurbished units, giving the company 15 days to respond.